Global Computational Biology Market Revenue Will Grow To

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Global Computational Biology Market Revenue Will Grow To $4,285.1 Million By 2020: New Report By Grand View Research, Inc.

San Francisco, California, Nov. 18, 2014 (GLOBE NEWSWIRE) -- The global market for computational biology is expected to reach USD 4,285.1 million by 2020 growing at a CAGR of 21.1%, according to a new study by Grand View Research, Inc. Steady increase in the usage & application of computational biology for bioinformatics R&D programs designed for sequencing genomes to better understand biological systems and increasing number of clinical studies in pharmacogenomics and pharmacokinetics for novel drug discovery studies are expected to drive computational biology demand over the next six years.

Computational genomics for cellular and biological simulation applications dominated the market in 2013, accounting for over 47% of global revenue. Key factors driving demand for these applications include the growth of drug designing, disease modeling and personalized medicine applications and the growing usage of computational biology for functional and structural genomics, epigenomics and metagenomics for the analysis of protein transcription, protein-protein interactions, gene sequencing and expression and 3-dimensional protein structure analysis.

Get More Details About Computational Biology Market: http://www.grandviewresearch.com/industry-ana...ogy-market

Further key findings from the study suggest:

  • North America was the largest regional market, accounting for 58.0% of the global revenue in 2013. Its large share is majorly attributed to the growing research investments and initiatives for development of drug discovery, disease modeling technologies and innovations in biological computation methods. It is expected that Asia Pacific will witness the fastest growth in the market, at an estimated CAGR of 28.0% owing to the increasing expenditure in clinical studies for pharmacokinetics and pharmacogenomics.
  • The application of computational biology in proteomics for cellular simulation is expected to grow at the fastest CAGR of over 22% owing to the shift in sequencing studies towards further analysis of the nature of various biological proteins as a part of development of personalized medicine.
  • Drug discovery and disease modelling applications dominated the market, accounting for 58.0% of global revenue in 2013. This large share is attributed by the extensive drug development pipelines present for a number of global branded and generic drug manufacturing firms such as Sanofi, Novo Nordisk and Eli Lilly.
  • Computational Biology databases dominated the tools segment and accounted for 44.5% of the market revenue in 2013, owing to extensive genomic database usage for warehousing and data mining of biological and sequential data generated from genomic and proteomic studies. Consequentially, the software and services for the analysis of biological data is expected to witness the fastest CAGR of over 21.0%.
  • Key players of this market include Schrodinger, Accelrys, Certara, Entelos, Simulation Plus and others.

Full Research Report On "Global Computational Biology Market": http://www.grandviewresearch.com/industry-ana...ogy-market

For the purpose of this study, Grand View Research has segmented the computational biology market on the basis of applications, tools, services, end users and region:

Computational Biology Application Outlook
    • Cellular & Biological Simulation
            • Computational Genomics
            • Computational Proteomics
            • Pharmacogenomics
            • Others (Transcriptomics/Metabolomics)
    • Drug Discovery and Disease Modelling
            • Target Identification
            • Target Validation
            • Lead Discovery
            • Lead Optimization
    • Preclinical Drug Development
            • Pharmacokinetics
            • Pharmacodynamics
    • Clinical trials
            • Phase I
            • Phase II
            • Phase III
    • Human Body Simulation Software
Computational Biology Tools Outlook
    • Databases
    • Infrastructure (Hardware)
    • Analysis Software & Services
Computational Biology Services Outlook
    • In-house
    • Contract
Computational Biology End User Outlook
    • Academics
    • Industry
    • Commercial
Computational Biology Regional Outlook
    • North America
    • Europe
    • Asia Pacific
    • RoW

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: www.grandviewresearch.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 120

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 115

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
Another Nine's A9OS Puts Software at Center of Golf

Updated Category News Views 63

A golf simulator chain is trying to turn the boring plumbing into its sharpest club. Another Nine’s A9OS is not merely a booking widget dressed up for a franchise brochure; it is meant to run the whole 24/7 operation, from payments and door access to cameras, simulator support and guest help. That ambition deserves attention because this is exactly where a staff-free...

Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum

Updated Category News Views 43

Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...

Continue Reading
Jumia’s Breakeven Retreat Invites Legal Scrutiny

Updated Category News Views 63

Jumia’s credibility problem did not arrive wearing a disguise. The company spent much of 2026 telling investors that a fourth-quarter Adjusted EBITDA breakeven was still on the table, then discarded that target after reporting third-quarter results. For holders of NYSE:JMIA, that kind of reversal stings because the promise was not some stray talking point; it was...

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 87

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
Yoodli's No. 9 Ranking Signals Enterprise AI Traction

Updated Category News Views 102

Ninth place can be easy to dismiss until you notice the company is sitting near the top of a 500-name growth list. Yoodli's No. 9 position on Deloitte's 2026 Technology Fast 500 is a meaningful signal that its AI-based coaching and workforce-skills pitch is getting traction inside large organizations. It is not a revenue disclosure, it is not a valuation marker, and...

Continue Reading
Paladone Tests LEGO's Everyday Collectibles Pull Abroad

Updated Category News Views 139

A glowing minifigure lamp is not exactly a macroeconomic event, but licensed merchandise has a funny way of revealing where household spending still has a pulse. Paladone Products has put its first LEGO-branded collection into stores, a modest-looking launch with some real retail logic behind it. This is not a grand toy-box bet on one blockbuster item. It is a spread of...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 17

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 121

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading

Top 5 Most Recently Viewed Articles

Nvidia's Strategic Path in AI and Future Possibilities

Updated Category News Views 133

Nvidia's rise as a leader in artificial intelligence was no accident. The tech giant smashed revenue and profit records that had traders buzzing back then. Everyone who jumped on Nvidia over the past couple of years likely scored some serious gains. But here's where it gets tricky: what’s next? Long-term thinking is crucial; it's one thing to ride the wave when...

Continue Reading
Exploring the Rise of AvaTrade and Its User-Friendly App

Updated Category News Views 167

Understanding AvaTrade – A Comprehensive Trading Platform AvaTrade is a highly regarded global trading platform founded to offer access to a variety of financial markets. With licenses from multiple recognized regulatory bodies, the platform ensures high standards of transparency and investor protection, allowing users to engage in trading with confidence. Wide Range of...

Continue Reading
Honka Fusion+: A Breakthrough in Sustainable Wood Construction

Updated Category News Views 192

Honka Fusion+: A Breakthrough in Sustainable Wood Construction Honka, a leader in the realm of modern wood construction, has recently introduced an exciting innovation in the form of Honka Fusion+. This new generation of non-settling CLT (cross-laminated timber) logs is set to revolutionize the construction industry by pushing the boundaries of what can be achieved with...

Continue Reading
Analyzing Recent Trading Trends for Honeywell International

Updated Category News Views 152

Understanding Current Options Trading Dynamics for Honeywell Intl Investors with significant financial resources have recently exhibited a bullish sentiment towards Honeywell International (NASDAQ: HON). This trend is noteworthy and should certainly be on the radar of market participants. Our observations from the public options data highlight this noticeable movement...

Continue Reading
Lineage, Inc. Faces Class Action Lawsuit Over Fraud Allegations

Updated Category News Views 217

Investors Encouraged to Act on Lineage, Inc. Class Action In light of recent developments, investors in Lineage, Inc. are strongly urged to engage with Kirby McInerney LLP regarding a class action lawsuit stemming from alleged securities fraud. This legal action is specifically focused on investors who acquired Lineage securities during a defined period, particularly...

Continue Reading